SCHEMBL4153922

SCHEMBL4153922

Cc1cc(-c2ccc3nccc(N)c3c2)ccc1F

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.53
MAP4K4 O95819 10/20 0.49
NCF1 P14598 1/20 0.42
KDR P35968 2/20 0.42
PIK3CD O00329 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
HCK P08631 1/20 0.42
SRC P12931 1/20 0.42
PIK3CA P42336 1/20 0.42
PIK3CB P42338 1/20 0.42
MTOR P42345 1/20 0.42
PIK3CG P48736 1/20 0.42
EPHB4 P54760 1/20 0.42
PRKDC P78527 1/20 0.42
AURKA O14965 1/20 0.42
DAPK3 O43293 1/20 0.42
JAK2 O60674 1/20 0.42
PRKD3 O94806 1/20 0.42
PAK4 O96013 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4139488 0.88 NR4A2 (0.49) NR4A2MAP4K4NCF1KDRPIK3CD
SCHEMBL15638701 0.85 TGFBR1 (0.53) NR4A2MAP4K4KDRPIK3CDABL1
SCHEMBL4156985 0.78 RAF1 (0.53) NR4A2MAP4K4METALDH1A1
SCHEMBL29061683 0.76 MAP4K4 (0.60) NR4A2MAP4K4NCF1KDRPIK3CD
SCHEMBL4151090 0.76 MAP4K4 (0.60) NR4A2MAP4K4NCF1KDRPIK3CD
SCHEMBL29165055 0.75 NR4A2 (0.42) NR4A2MAP4K4NCF1KDRPIK3CD
SCHEMBL4155195 0.74 NR4A2 (0.54) NR4A2MAP4K4NCF1KDRPIK3CD
SCHEMBL8306581 0.73 NR4A2 (0.61) NR4A2NCF1KDRPIK3CDABL1
SCHEMBL16446547 0.73 NR4A2 (0.61) NR4A2MAP4K4NCF1CDK8SOS2
SCHEMBL14145821 0.73 NR4A2 (0.49) NR4A2MAP4K4NCF1KDRPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds DICKSON JR JOHN K 2009-03-12 US disclosed
US-7452887-B2 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AMPHORA DISCOVERY CORPORATION (US) 2008-11-18 US disclosed
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof AGRIUS GROUP, LLC. 2006-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069338-A1 Method for predicting skin sensitizing activity of compounds ATP5ME, ABCG2, ATP5MG NR4A2 1882/4885MAP4K4 1842/4885NCF1 672/4885
US-20060009460-A1 Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof ATP5ME, ATP5MG, ATP5MK NR4A2 3517/4885MAP4K4 1968/4885NCF1 2180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.